Skip to content

Incidence of phlebitis with peripheral intravenous catheter in patients admitted in intensive care unit

Incidence of Phlebitis with Peripheral Intravenous Catheter - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/103497
Enrollment
150
Registered
2026-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism Health Condition 2: I00-I99- Diseases of the circulatory system Health Condition 3: K00-K95- Diseases of the digestive system Health Condition 4: N00-N99- Diseases of the genitourinary system Health Condition 5: M00-M99- Diseases of the musculoskeletal system and connective tissue Health Condition 6: G00-G99- Diseases of the nervous system Health Condition 7: J00-J99-

Interventions

Intervention1: Nil: Nil

Sponsors

Apollo Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adult patients greater than 18years of age admitted in ICU.

Exclusion criteria

Exclusion criteria: Patients with pre existing skin diseases. Patients with history of allergy to medications. Burn patients.

Design outcomes

Primary

MeasureTime frame
To identify the incidence of phlebitis with peripheral iv catheter insertion.Timepoint: For a period of 7 days from the time of admission or upto their discharge from ICU, whichever occurs first.

Secondary

MeasureTime frame
To identify the risk factors for the development of phlebitis.Timepoint: For a period of 7 days from the time of admission or upto their discharge from icu, whichever occurs first

Countries

India

Contacts

Public ContactDr Suresh Kumar Sundaramurthy

Apollo Hospital

surkum85@gmail.com9999942084

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026